A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

N/ANo Longer AvailableNCT00801515

ViiV Healthcare

Overview

This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.

Study Type

EXPANDED_ACCESS

Conditions

HIV

Interventions

MaravirocDRUG

150 mg twice per day

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients having completed study A4001029 in Canada and still deriving clinical benefit. Exclusion Criteria: * None

Locations (1)

Pfizer Investigational Site

Montreal, Quebec, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.